Tumor-infiltrating lymphocyte therapy expands past melanoma
TIL therapy approval in metastatic melanoma is opening pathways into cervical and other solid tumour indications.
Tumor-infiltrating lymphocyte (TIL) therapy now has approval in metastatic melanoma after multiple checkpoint failures. Late-stage programs are testing TIL therapy in cervical and other solid tumour indications. The operational footprint resembles CAR-T (apheresis, ex-vivo expansion, lymphodepletion before infusion) which means the modality lives in centres of excellence rather than community oncology.
Continue reading
Full intelligence on PanaceaIntel
PatientSpotlight publishes the headline framing. The full brief, the editorial takeaway, and the source list sit on PanaceaIntel for entitled clients.
New to PanaceaIntel? Request access and the team will reply within one working day.